KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) Other Non Operating Income (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 12 years of Other Non Operating Income data on record, last reported at $176.0 million in Q4 2025.

  • For Q4 2025, Other Non Operating Income rose 914.81% year-over-year to $176.0 million; the TTM value through Dec 2025 reached $1.7 billion, up 100.92%, while the annual FY2025 figure was $1.7 billion, 100.92% up from the prior year.
  • Other Non Operating Income reached $176.0 million in Q4 2025 per REGN's latest filing, down from $755.8 million in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $755.8 million in Q3 2025 and bottomed at -$183.8 million in Q1 2022.
  • Average Other Non Operating Income over 5 years is $202.1 million, with a median of $184.5 million recorded in 2023.
  • The widest YoY moves for Other Non Operating Income: up 1937.8% in 2022, down 218.66% in 2022.
  • A 5-year view of Other Non Operating Income shows it stood at -$16.4 million in 2021, then skyrocketed by 1290.85% to $195.3 million in 2022, then dropped by 1.18% to $193.0 million in 2023, then crashed by 111.19% to -$21.6 million in 2024, then soared by 914.81% to $176.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non Operating Income were $176.0 million in Q4 2025, $755.8 million in Q3 2025, and $442.8 million in Q2 2025.